Clinical trials: Covid-19 Patients
Covid19
Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection
Multicentre, multinational, non-interventional, observational, retrospective, patient record study to evaluate changes in coagulation parameters in patients with severe COVID-19 infection receiving/not treatment with antithrombin…
- Trial name
- NCT04651400
- Testing
- Antithrombin III
- Where
- 6 sites in Austria, France and 2 more
- Volunteers
- 300 people
- Sponsor
- Octapharma
COVID-19
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization…
- Trial name
- LUNAR (NCT05305651)
- Testing
- Sotrovimab
- Where
- 8 sites in United Kingdom
- Volunteers
- 217 people
- Sponsor
- GlaxoSmithKline
Covid19
Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
This is a 2-part, 2-arm, Phase 2 , multicentre, randomized, double-blind, placebo-controlled study in adults with COVID-19 with gastrointestinal infection.
- Trial name
- RESERVOIR (NCT04858425)
- Testing
- Niclosamide
- Where
- 25 sites in United States, India and 1 more
- Volunteers
- 166 people
- Sponsor
- Entero Therapeutics
Covid19
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
This is an interventional, multicenter, 2-arm, parallel-group, randomized, double-blind, placebo controlled, dose-escalation, safety and efficacy study of F-652 treatment versus placebo in patients aged 18 years or older with a…
- Trial name
- NCT04498377
- Testing
- F-652
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- EVIVE Biotechnology
Acute Respiratory Distress Syndrome, Coronavirus
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical…
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure
- Trial name
- VANGARD (NCT04433546)
- Testing
- Pemziviptadil (PB1046), Low Dose (10 mg) Control
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
COVID-19, Coronavirus
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning
The purpose of this study was to assess the performance of a machine learning algorithm which identifies patients for whom hydroxychloroquine treatment is associated with predicted survival.
- Conditions
- COVID-19, Coronavirus, Mortality
- Trial name
- IDENTIFY (NCT04423991)
- Testing
- COViage
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Dascena
COVID
Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
GC004 is a Phase I trial to evaluate the safety and the immune responses of a therapeutic vaccine in SARS-CoV-2 infected patients.
- Trial name
- NCT04428073
- Testing
- Covax-19™
- Volunteers
- 32 people
- Sponsor
- GeneCure Biotechnologies
COVID-19
Desidustat in the Management of COVID-19 Patients
This study is a Phase 2b, Multicenter, Open-label, Randomized, Comparator- Controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of mild, moderate and severe COVID-19 patients.
- Trial name
- NCT04463602
- Testing
- Desidustat, Standard of Care
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- Zydus Lifesciences Limited
Post COVID-19 Condition
Post-COVID-19 Patients With Trak Tool
The clinical trial aims to analyse the effectiveness of a physiotherapeutic exercise program delivered through the telerehabilitation tool (Trak) compared to a booklet-based rehabilitation format in post-COVID-19 patients.
- Trial name
- TRAK-COVID (NCT06492551)
- Testing
- Trak exercise prescription protocol, Conventional rehabilitation plan in the gym
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Trak Health Solutions S.L.
Covid19
Retrospective Study of ImmunoFormulation for COVID-19
Multicentre, retrospective, observational study to describe the course of SARS-CoV-2 disease in patients treated or not with IMUNO TF ® and a combination of nutraceuticals and who have tested positive in a COVID-19 diagnostic…
- Trial name
- NCT04666753
- Testing
- ImmunoFormulation
- Where
- 2 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fagron Iberica S.A.U.
Covid-19
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19
This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (500 mg/ 5 days) to treat mild ambulatory COVID-19 patients.
- Trial name
- NCT04348474
- Testing
- Hydroxychloroquine Sulfate, Azithromycin Tablets
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- Azidus Brasil
Long COVID, Post-COVID Syndrome
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.
- Conditions
- Long COVID, Post-COVID Syndrome, Post COVID-19 Condition
- Trial name
- NCT05682560
- Testing
- REGENECYTE
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- StemCyte, Inc.
Influenza Infection, SAD-RV Infection and COVID-19
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.
- Trial name
- STOP-Flu (NCT04298060)
- Testing
- DAS181
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Ansun Biopharma, Inc.
Covid19
Study of Codivir in Patients With COVID-19
This is an open-label study to evaluate the safety and preliminary efficacy of Codivir in 12 mild or moderate COVID-19 patients and onset of symptoms within 72h prior to their inclusion.
- Trial name
- Codivir (NCT04930861)
- Testing
- Covidir injections, One Step Test, IgM and IgG dosage
- Where
- Brazil
- Volunteers
- 12 people
- Sponsor
- Code Pharma
SARS-CoV-2 Infection, Anti-SARS-CoV-2 Infection
Registry of Sustained Immunity to COVID-19 Among ESKD Patients
This is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a DaVita center.
- Trial name
- RePAiR (NCT04495764)
- Where
- 12 sites in United States
- Volunteers
- 2,315 people
- Sponsor
- Davita Clinical Research
COVID-19
Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19
This is a multicenter, double-blind, randomized, placebo-controlled, loaded Phase III clinical study. This test is in a new coronavirus infection pneumonia diagnosis and treatment plan of 9 (trial version) "(SoC), on the basis of…
- Trial name
- NCT05679479
- Testing
- Meplazumab for injection, Normal saline
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
COVID-19 Patients, Hypoxemic Respiratory Failure
Awake Prone Positioning in COVID-19 Suspects With Hypoxemic Respiratory Failure
The investigator hypothesis is that early implementation of early, awake prone position for patients with COVID-19 pneumonia requiring oxygen therapy will reduce the need for escalation of respiratory support.
- Conditions
- COVID-19 Patients, Hypoxemic Respiratory Failure, Prone Position
- Trial name
- NCT04853979
- Testing
- PRONE POSITION
- Where
- Qatar
- Volunteers
- 61 people
- Sponsor
- Hamad Medical Corporation
Sars-CoV-2 Infection
A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19
The innovative drug XC221 100 mg tablet is designed for the treatment of COVID-19 (SARS-CoV-2 infection). A multicenter, adaptive, randomized, double-blind, placebo-controlled Phase III clinical study is aimed to assess the…
- Trial name
- NCT04940182
- Testing
- XC221
- Where
- 11 sites in Russia
- Volunteers
- 274 people
- Sponsor
- RSV Therapeutics LLC
SARS-CoV-2 Infection
Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.
This is a randomized, double-blind, placebo-controlled study of RP7214 in patients with symptomatic mild SARS-CoV-2 infection, having at least one high-risk feature (e.g., age > 60 years, hypertension, diabetes mellitus, chronic…
- Trial name
- NCT05007236
- Testing
- RP7214 + Standard of care (SOC)
- Where
- 16 sites in India
- Volunteers
- 163 people
- Sponsor
- Rhizen Pharmaceuticals SA
Severe COVID-19
Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients
Efficacy and Safety of DWJ1248 with Remdesivir in Severe COVID-19 Patients
- Trial name
- NCT04713176
- Testing
- DWJ1248 with Remdesivir
- Where
- South Korea
- Volunteers
- 240 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.